Finance

Lists
DYN:NASDAQ
Dyne Therapeutics, Inc
$26.25
+1.43%
(+0.37) 1D
$26.25
0.00% (0.00)
After hours
Closed: Aug 7, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for DYN...
Open
$26.20
High
$26.34
Low
$25.24
Mkt. cap
4.90B
Avg. vol.
2.61M
Volume
1.99M
52-wk high
$27.09
52-wk low
$10.78
EPS
-$3.33
Beta
1.07
Shares outstanding
186.75M
No. of employees
289
Open
$26.20
High
$26.34
Low
$25.24
Mkt. cap
4.90B
Avg. vol.
2.61M
Volume
1.99M
52-wk high
$27.09
52-wk low
$10.78
EPS
-$3.33
Beta
1.07
Shares outstanding
186.75M
No. of employees
289
News stories
From sources across the web
About Dyne Therapeutics, Inc
CEO-
Employees289
Founded2017
HeadquartersWaltham, Massachusetts, United States
SectorBiotechnology
Websitedyne-tx.com
Analyst ratings
Based on 14 analysts giving stock ratings to DYN in the past 3 months
Strong buy
Buy
12
Hold
2
Sell
0
12-month forecast
Based on 14 Wall Street analysts offering 12 month price targets for DYN in the last 3 months.
Highest
Current $26.25
$50.00 (+90.48%)
Average
$40.27 (+53.41%)
Lowest
$24.00 (-8.57%)
Analyst
Recommendation
Action
Price target
Projected
Date
Martin Auster
Raymond James
Buy
Maintained
$40.00
+52.4%
08/04/2026
Tessa Romero
J.P. Morgan
Hold
Reiterated
-
-
07/30/2026
Paul Matteis
Stifel Nicolaus
Buy
Maintained
$37.00
+41%
07/31/2026
Luca Issi
RBC Capital
Buy
Reiterated
$35.00
+33.3%
07/29/2026
Edward Tenthoff
Piper Sandler
Buy
Reiterated
$47.00
+79%
07/30/2026
Keay Nakae
Chardan Capital
Buy
Maintained
$38.00
+44.8%
07/29/2026
Francois Brisebois
LifeSci Capital
Buy
Reiterated
$44.00
+67.6%
07/31/2026
Michael Ulz
Morgan Stanley
Buy
Maintained
$45.00
+71.4%
07/31/2026
Joseph Thome
TD Cowen
Buy
Maintained
-
-
07/28/2026
Gavin Clark-Gartner
Evercore ISI
Buy
Maintained
$33.00
+25.7%
07/27/2026
Eric Schmidt FCA
Cantor Fitzgerald
Buy
Initiated
-
-
07/23/2026
Unknown Analyst
J.P. Morgan
Hold
Maintained
-
-
07/20/2026
Unknown Analyst
Guggenheim
Buy
Maintained
$50.00
+90.5%
06/30/2026
Ananda Ghosh
H.C. Wainwright
Buy
Maintained
$50.00
+90.5%
05/21/2026
Andreas Argyrides
Chardan Capital
Buy
Reiterated
$40.00
+52.4%
05/21/2026
William Pickering
Bernstein
Hold
Reiterated
$24.00
-8.6%
05/13/2026
Last report
Jul 29, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$1.08 / -$0.75
-44.28%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
97.22M
95.43M
100.89M
152.17M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
16.67M
20.70M
24.39M
29.49M
Operating expense
113.89M
116.13M
125.28M
181.66M
Total operating expenses
113.89M
116.13M
125.28M
181.66M
Operating income
-113.89M
-116.13M
-125.28M
-181.66M
Other non operating income
-
-
-233.00K
12.00K
EBT including unusual items
-108.04M
-111.96M
-120.85M
-178.56M
EBT excluding unusual items
-108.04M
-111.97M
-120.85M
-178.56M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-108.04M
-111.96M
-120.85M
-178.56M
Net profit margin
-
-
-
-
Earnings per share
-0.76
-0.73
-0.73
-1.08
Interest and investment income
8.48M
7.66M
8.76M
7.79M
Interest expense
-2.90M
-3.19M
-4.20M
-4.60M
Net interest expenses
5.57M
4.46M
4.56M
3.19M
Depreciation and amortization charges
-
-
-
-
EBITDA
-113.37M
-115.61M
-124.73M
-181.10M
Gain or loss from assets sale
-
-
30.00K
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps